TABLE 2.
Effect of peptides on graft-associated infections in rats
| Treatmenta | Soaking solution (mg/liter) | MRSA (mean CFU/ml ± SD) | MRSE (mean CFU/ml ± SD) |
|---|---|---|---|
| None (control) | 0 | 4.4 × 106 ± 1.2 × 106 | 6.9 × 106 ± 1.8 × 106 |
| RIP* | 10 | 4.1 × 104 ± 7.1 × 103 | 6.9 × 103 ± 1.9 × 103 |
| 20 | 5.9 × 103 ± 1.7 × 103 | 8.5 × 102 ± 2.0 × 102 | |
| 50 | 84 ± 36 | 39 ± 16 | |
| DD13* | 10 | 5.8 × 102 ± 2.1 × 102 | 5.2 × 102 ± 1.6 × 102 |
| 20 | 40 ± 17 | 44 ± 13 | |
| 50 | <10 | <10 | |
| DD13-RIP* | 10 | 19 ± 3 | 30 ± 7 |
| 20 | <10 | <10 | |
| 50 | <10 | <10 |
a
Dacron grafts were presoaked in saline (control), RIP, DD13, or DD13-RIP at the designated concentrations and implanted in rats (15 rats per group). Grafts were then inoculated with MRSA or a clinical isolate of MRSE. Grafts were removed after a week, and CFU were determined. *, P < 0.05 compared to control untreated group. Detection limit, 10 CFU/ml.